Merck & Co. Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) increased by 80.0% to $2.70B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 80.0%, from $1.50B to $2.70B. Over 5 years (FY 2020 to FY 2025), Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) shows an upward trend with a 17.6% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Higher values indicate a larger near-term drag on reported earnings due to previous acquisition activity.
This represents the projected non-cash expense related to the amortization of finite-lived intangible assets for the upc...
Companies with high M&A activity in the medical device space typically report significant annual amortization expenses.
finite_lived_intangible_assets_amortization_year_1| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|---|---|
| Value | $1.40B | $1.30B | $1.10B | $1.50B | $2.70B |
| QoQ Change | — | -7.1% | -15.4% | +36.4% | +80.0% |
| YoY Change | — | -7.1% | -15.4% | +36.4% | +80.0% |